ROSE-AHF and lessons learned

Amit K. Jain, Horng H. Chen

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Nesiritide and dopamine have been recognized for some time as potential renal adjunct therapies in the management of patients with acute heart failure (AHF). Several studies have yielded conflicting evidence of the efficacy of both medications in enhancing the renal function of patients with AHF. The Renal Optimization Strategies Evaluation (ROSE) study was a multicenter double-blind placebo controlled trial designed to assess the potential renoprotective effects of low-dose nesiritide and dopamine in AHF patients with renal dysfunction. This article will focus on previous research, summary of results, and lessons learned from the ROSE-AHF trial as well as future directions for clinical research and applications.

Original languageEnglish (US)
Pages (from-to)260-265
Number of pages6
JournalCurrent heart failure reports
Issue number3
StatePublished - Sep 2014


  • Acute heart failure
  • Dopamine
  • Heart failure therapy
  • Natriuretic peptides
  • Nesiritide
  • Renal dysfunction

ASJC Scopus subject areas

  • Emergency Medicine
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)


Dive into the research topics of 'ROSE-AHF and lessons learned'. Together they form a unique fingerprint.

Cite this